🖐 Scleroderma Internal Organ Involvement Screening Simulator

Screening for Interstitial Lung Disease

Placeholder lead: PFT and HRCT catch early fibrosis before symptoms appear.

• ~45%: ILD prevalence (placeholder stat)
• 6–12 mo: PFT interval (placeholder stat)
• FVC drop: HRCT trigger (placeholder stat)
• DLCO: Key test (placeholder stat)

PFT and HRCT basics

Placeholder: spirometry and diffusion capacity track early lung fibrosis.

Placeholder insight: annual PFT is the frontline screening test.

Echocardiographic PH Screening

Placeholder lead: echo estimates pulmonary pressure to catch PH early.

• ~15%: PH prevalence (placeholder stat)
• Annual: Echo interval (placeholder stat)
• RHC: Confirm test (placeholder stat)
• PASP: Key marker (placeholder stat)

Echo-based PH detection

Placeholder: tricuspid regurgitant jet velocity estimates PASP.

Placeholder insight: right heart catheterization confirms diagnosis.

Blood Pressure and Creatinine Monitoring

Placeholder lead: renal crisis risk peaks early in diffuse disease.

• 0–4 yr: Peak window (placeholder stat)
• Daily: BP self-check (placeholder stat)
• ACE-i: Key drug class (placeholder stat)
• Cr rise: Warning sign (placeholder stat)

Renal crisis warning signs

Placeholder: new hypertension plus rising creatinine signals crisis.

Placeholder insight: early ACE inhibitor use improves outcomes.

ECG and Echo Cardiac Screening

Placeholder lead: myocardial fibrosis and arrhythmia need routine screening.

• ~25%: Cardiac involvement (placeholder stat)
• Annual: ECG interval (placeholder stat)
• Cardiac MRI: Imaging option (placeholder stat)
• Diffuse skin: Risk factor (placeholder stat)

Detecting cardiac fibrosis

Placeholder: ECG and echo screen for conduction and wall changes.

Placeholder insight: cardiac MRI detects subclinical fibrosis.

Composite Multi-Organ Risk Overview

Placeholder lead: combining organ risks sets a personalized screening plan.

• 3: Organs tracked (placeholder stat)
• PFT/Echo/BP: Tests combined (placeholder stat)
• Risk-based: Review interval (placeholder stat)
• Early detection: Goal (placeholder stat)

Putting it together

Placeholder: combined risk score sets screening frequency and priority.

Placeholder insight: multidisciplinary follow-up improves survival.